Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis

Alessia Giorgini, Franco Capsoni, Mauro Podda, Ana Lleó, Pier Maria Battezzati, Anna Maria Ongari, Carlo Selmi, Alberto Benetti, Federica Malinverno, Lorenzo Rossaro, M. Eric Gershwin, Massimo Zuin

Research output: Chapter in Book/Report/Conference proceedingConference contribution

11 Citations (Scopus)

Abstract

The incidence of infections increases during treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) for chronic hepatitis C (CHC). Despite a reduction in neutrophil count, there is no clear relationship between infection occurrence and neutropenia. In the present study we investigated whether HCV treatment alters leukocyte function. We studied cell chemotaxis, reactive oxygen species, neutrophil phagocytosis, CR3 expression, and plasma colony stimulating factors (CSF) in 20 healthy subjects and 20 patients with CHC (10 with cirrhosis) at baseline, during antiviral treatment (at 4, 12, 24 weeks), and 12 weeks after discontinuation. Our results demonstrate that neutrophil chemotaxis and oxidative burst significantly increased during treatment and returned to baseline at the end of therapy. CR3 neutrophil expression was enhanced in baseline CHC compared to controls but did not change during antiviral treatment. Chemotaxis, oxidative burst, phagocytosis, and CSF levels did not differ significantly between patients before treatment and control subjects or among CHC cases according to the presence of cirrhosis in either cell subpopulation. In conclusion, the innate immune cell activity is enhanced in patients with CHC during antiviral treatment and returns to normal after its discontinuation thus possibly playing a role in their susceptibility to infections.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Pages847-857
Number of pages11
Volume1173
DOIs
StatePublished - Sep 2009

Publication series

NameAnnals of the New York Academy of Sciences
Volume1173
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Ribavirin
Chronic Hepatitis C
Chemotaxis
Interferons
Polyethylene glycols
Antiviral Agents
Colony-Stimulating Factors
Monocytes
Neutrophils
Patient treatment
Respiratory Burst
Reactive Oxygen Species
Therapeutics
Plasmas
Fibrosis
Infection
Neutropenia
Phagocytosis
Healthy Volunteers
Leukocytes

Keywords

  • Leukocyte function
  • Opportunistic infection
  • Pegylated interferon
  • Ribavirin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Giorgini, A., Capsoni, F., Podda, M., Lleó, A., Battezzati, P. M., Ongari, A. M., ... Zuin, M. (2009). Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. In Annals of the New York Academy of Sciences (Vol. 1173, pp. 847-857). (Annals of the New York Academy of Sciences; Vol. 1173). https://doi.org/10.1111/j.1749-6632.2009.04623.x

Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. / Giorgini, Alessia; Capsoni, Franco; Podda, Mauro; Lleó, Ana; Battezzati, Pier Maria; Ongari, Anna Maria; Selmi, Carlo; Benetti, Alberto; Malinverno, Federica; Rossaro, Lorenzo; Gershwin, M. Eric; Zuin, Massimo.

Annals of the New York Academy of Sciences. Vol. 1173 2009. p. 847-857 (Annals of the New York Academy of Sciences; Vol. 1173).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Giorgini, A, Capsoni, F, Podda, M, Lleó, A, Battezzati, PM, Ongari, AM, Selmi, C, Benetti, A, Malinverno, F, Rossaro, L, Gershwin, ME & Zuin, M 2009, Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. in Annals of the New York Academy of Sciences. vol. 1173, Annals of the New York Academy of Sciences, vol. 1173, pp. 847-857. https://doi.org/10.1111/j.1749-6632.2009.04623.x
Giorgini A, Capsoni F, Podda M, Lleó A, Battezzati PM, Ongari AM et al. Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. In Annals of the New York Academy of Sciences. Vol. 1173. 2009. p. 847-857. (Annals of the New York Academy of Sciences). https://doi.org/10.1111/j.1749-6632.2009.04623.x
Giorgini, Alessia ; Capsoni, Franco ; Podda, Mauro ; Lleó, Ana ; Battezzati, Pier Maria ; Ongari, Anna Maria ; Selmi, Carlo ; Benetti, Alberto ; Malinverno, Federica ; Rossaro, Lorenzo ; Gershwin, M. Eric ; Zuin, Massimo. / Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. Annals of the New York Academy of Sciences. Vol. 1173 2009. pp. 847-857 (Annals of the New York Academy of Sciences).
@inproceedings{6dcb75fae9334bdd99754df24a4f1628,
title = "Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis",
abstract = "The incidence of infections increases during treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) for chronic hepatitis C (CHC). Despite a reduction in neutrophil count, there is no clear relationship between infection occurrence and neutropenia. In the present study we investigated whether HCV treatment alters leukocyte function. We studied cell chemotaxis, reactive oxygen species, neutrophil phagocytosis, CR3 expression, and plasma colony stimulating factors (CSF) in 20 healthy subjects and 20 patients with CHC (10 with cirrhosis) at baseline, during antiviral treatment (at 4, 12, 24 weeks), and 12 weeks after discontinuation. Our results demonstrate that neutrophil chemotaxis and oxidative burst significantly increased during treatment and returned to baseline at the end of therapy. CR3 neutrophil expression was enhanced in baseline CHC compared to controls but did not change during antiviral treatment. Chemotaxis, oxidative burst, phagocytosis, and CSF levels did not differ significantly between patients before treatment and control subjects or among CHC cases according to the presence of cirrhosis in either cell subpopulation. In conclusion, the innate immune cell activity is enhanced in patients with CHC during antiviral treatment and returns to normal after its discontinuation thus possibly playing a role in their susceptibility to infections.",
keywords = "Leukocyte function, Opportunistic infection, Pegylated interferon, Ribavirin",
author = "Alessia Giorgini and Franco Capsoni and Mauro Podda and Ana Lle{\'o} and Battezzati, {Pier Maria} and Ongari, {Anna Maria} and Carlo Selmi and Alberto Benetti and Federica Malinverno and Lorenzo Rossaro and Gershwin, {M. Eric} and Massimo Zuin",
year = "2009",
month = "9",
doi = "10.1111/j.1749-6632.2009.04623.x",
language = "English (US)",
isbn = "9781573317627",
volume = "1173",
series = "Annals of the New York Academy of Sciences",
pages = "847--857",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis

AU - Giorgini, Alessia

AU - Capsoni, Franco

AU - Podda, Mauro

AU - Lleó, Ana

AU - Battezzati, Pier Maria

AU - Ongari, Anna Maria

AU - Selmi, Carlo

AU - Benetti, Alberto

AU - Malinverno, Federica

AU - Rossaro, Lorenzo

AU - Gershwin, M. Eric

AU - Zuin, Massimo

PY - 2009/9

Y1 - 2009/9

N2 - The incidence of infections increases during treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) for chronic hepatitis C (CHC). Despite a reduction in neutrophil count, there is no clear relationship between infection occurrence and neutropenia. In the present study we investigated whether HCV treatment alters leukocyte function. We studied cell chemotaxis, reactive oxygen species, neutrophil phagocytosis, CR3 expression, and plasma colony stimulating factors (CSF) in 20 healthy subjects and 20 patients with CHC (10 with cirrhosis) at baseline, during antiviral treatment (at 4, 12, 24 weeks), and 12 weeks after discontinuation. Our results demonstrate that neutrophil chemotaxis and oxidative burst significantly increased during treatment and returned to baseline at the end of therapy. CR3 neutrophil expression was enhanced in baseline CHC compared to controls but did not change during antiviral treatment. Chemotaxis, oxidative burst, phagocytosis, and CSF levels did not differ significantly between patients before treatment and control subjects or among CHC cases according to the presence of cirrhosis in either cell subpopulation. In conclusion, the innate immune cell activity is enhanced in patients with CHC during antiviral treatment and returns to normal after its discontinuation thus possibly playing a role in their susceptibility to infections.

AB - The incidence of infections increases during treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) for chronic hepatitis C (CHC). Despite a reduction in neutrophil count, there is no clear relationship between infection occurrence and neutropenia. In the present study we investigated whether HCV treatment alters leukocyte function. We studied cell chemotaxis, reactive oxygen species, neutrophil phagocytosis, CR3 expression, and plasma colony stimulating factors (CSF) in 20 healthy subjects and 20 patients with CHC (10 with cirrhosis) at baseline, during antiviral treatment (at 4, 12, 24 weeks), and 12 weeks after discontinuation. Our results demonstrate that neutrophil chemotaxis and oxidative burst significantly increased during treatment and returned to baseline at the end of therapy. CR3 neutrophil expression was enhanced in baseline CHC compared to controls but did not change during antiviral treatment. Chemotaxis, oxidative burst, phagocytosis, and CSF levels did not differ significantly between patients before treatment and control subjects or among CHC cases according to the presence of cirrhosis in either cell subpopulation. In conclusion, the innate immune cell activity is enhanced in patients with CHC during antiviral treatment and returns to normal after its discontinuation thus possibly playing a role in their susceptibility to infections.

KW - Leukocyte function

KW - Opportunistic infection

KW - Pegylated interferon

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=69949150187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949150187&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.04623.x

DO - 10.1111/j.1749-6632.2009.04623.x

M3 - Conference contribution

C2 - 19758237

AN - SCOPUS:69949150187

SN - 9781573317627

VL - 1173

T3 - Annals of the New York Academy of Sciences

SP - 847

EP - 857

BT - Annals of the New York Academy of Sciences

ER -